昂利康(002940.SZ):擬出資3000萬元投設合資公司 以新建寵物專用藥品生產線
格隆匯8月20日丨昂利康(002940.SZ)公佈,2021年8月20日,公司與朱澤華簽訂《關於組建合資公司的合同》,共同投資設立合資公司。擬設立的合資公司為浙江昂利康動保科技有限公司(暫定名,“合資公司”),認繳出資總額為人民幣3000萬元,雙方均以自有資金出資,其中公司持有52%股權,朱澤華持有48%股權。
此次投資設立昂利康動保科技,是基於公司戰略發展需要,通過組建合資公司,新建寵物專用藥品生產線,推動寵物藥品的研發和產業化,有效整合合作雙方在生產製造和行業渠道的各自優勢。寵物用相關藥品如能研發併產業化成功,將進一步豐富公司的產品管線,拓展公司新的利潤增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.